masld glp 1 GLP-1 and Glucagon Receptor Dual Agonists in the Management of Metabolic Dysfunction-associated Steatotic Disease (MASLD) | Current Hepatology Reports GLP-1 therapies target MASLD/MASH pathophysiology
Description
When GIPR-Ab/GLP- 1 is used instead of GIPR-Ab or a control antibody conjugate, the body weight loss is higher, indicating synergistic effects
Surgical treatment may offer greater effectiveness at a lower cost than obesity management medication for the durable treatment of obesity
Various alternatives and considerations If monotherapy or dual-combination therapy fails to achieve the target HbA1c levels, a combination of three or more oral antidiabetic agents may be considered
These can include fainting and seizures
Why Switch
